^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Qibeian (iparomlimab/tuvonralimab)

    i
    Other names: PSB205 , PSB-205, PSB 205 , Anti-PD-1/CTLA-4 MabPair, QL1706, PBS-103/PBS-105, QL 1706, QL-1706
    Company:
    Qilu Pharma, Sound Biologics
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    4d
    QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Qibeian (iparomlimab/tuvonralimab)
    5d
    Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov)
    P2, N=39, Recruiting, Peking Union Medical College | Trial primary completion date: Jul 2026 --> Jul 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    carboplatin • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Piqray (alpelisib) • Irene (pyrotinib) • albumin-bound paclitaxel • abiraterone acetate • fulvestrant • Aidixi (disitamab vedotin) • exemestane • Padcev (enfortumab vedotin-ejfv) • bicalutamide • Kaitanni (cadonilimab) • goserelin acetate • Qibeian (iparomlimab/tuvonralimab) • Yidafan (ivonescimab) • iparomlimab (QL1604) • leuprolide acetate for depot suspension • Entyvio (vedolizumab)
    8d
    SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=89, Recruiting, Fujian Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jiataile (sacituzumab tirumotecan) • Qibeian (iparomlimab/tuvonralimab)
    8d
    A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Huazhong University of Science and Technology
    New P2 trial
    |
    Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P4, N=55, Not yet recruiting, Huazhong University of Science and Technology
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    11d
    Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    14d
    Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Changhai Hospital
    New P2 trial
    |
    cisplatin • carboplatin • Lenvima (lenvatinib) • albumin-bound paclitaxel • epacadostat (INCB024360) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial • Platinum sensitive
    |
    BRCA (Breast cancer early onset)
    |
    BRCA wild-type • BRCA mutation
    |
    Lynparza (olaparib) • carboplatin • paclitaxel • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    1m
    QLS5132 Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=626, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • cisplatin • carboplatin • oxaliplatin • Qibeian (iparomlimab/tuvonralimab)
    1m
    An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Peking Union Medical College Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Qibeian (iparomlimab/tuvonralimab)
    1m
    SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=42, Recruiting, Fujian Cancer Hospital | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2026 | Not yet recruiting --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    |
    capecitabine • oxaliplatin • Qibeian (iparomlimab/tuvonralimab)
    1m
    Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC (clinicaltrials.gov)
    P2, N=27, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial • Tumor mutational burden
    |
    EGFR (Epidermal growth factor receptor)
    |
    cisplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)